(Total Views: 519)
Posted On: 01/24/2021 2:51:52 PM
Post# of 154054
Please also note the below inclusion criteria is determined upon initial screening. Of course there will be many placebo patients who will progress into severe ARDS with the higher mortality rates. And as leronlimab works as we believe, the treatment arm will prevent this progression to severe disease.
I believe placebo group is less than 35%. The cd12 population specifically excludes the sickest of the sick on mechanical ventilation, which would have the highest mortality rate. So the 35% would need to be adjusted for this fact, but by how much, very difficult to tell.
CD12 Inclusion criteria:
3. Subject, if intubated, positive endexpiratory pressure (PEEP) <15 cmH2O with PaO2/FiO2 >150 mmHg.
The above criteria is for moderate ARDS. My interpretation is that including moderate ARDS only means severe ARDS (sickest of sick on mechanical ventilation) are excluded.
Read More: https://investorshangout.com/post/newpost/605...z6kUqEpolX
I believe placebo group is less than 35%. The cd12 population specifically excludes the sickest of the sick on mechanical ventilation, which would have the highest mortality rate. So the 35% would need to be adjusted for this fact, but by how much, very difficult to tell.
CD12 Inclusion criteria:
3. Subject, if intubated, positive endexpiratory pressure (PEEP) <15 cmH2O with PaO2/FiO2 >150 mmHg.
The above criteria is for moderate ARDS. My interpretation is that including moderate ARDS only means severe ARDS (sickest of sick on mechanical ventilation) are excluded.
Read More: https://investorshangout.com/post/newpost/605...z6kUqEpolX
(1)
(0)
